

4th International Conference on **Clinical & Experimental Dermatology**

April 14-16, 2014 Hilton San Antonio Airport, TX, USA

Weak points in clinical trials for aesthetic dermatology- How to improve?

Igor Rudenko

ICON Clinical Research, Germany

Current situation in Aesthetic Dermatology needs more evidence-based data for proving safety of drug, devices and techniques. Unfortunately not all clinical trials are based on the principles of GCP and some of them contain bias. Clinical data that received in such trials cannot be used for building science and serves only as clinical experience with lowest rate of EBM.

It was analyzed some clinical trials within aesthetic dermatology with revealing weak points and methods of their correction were proposed. Some clinical designs are demonstrated.

We can organize clinical trials with sufficient evidence rate only with full understanding principles of GCP and methodology of bias avoiding.

Biography

Igor Rudenko is an international speaker within Aesthetic and Dermatology fields: EMAA2012 (Paris), InterSharm2012 (Moscow), EAAD2012 (Moscow), DASIL2012 (Malta), IMCAS2013 - Paris, AWMC2013 - Monaco, NPI -ACCME course - Charleston, SC (2013), Vegas Cosmetic Surgery2013 (Las-Vegas). He is leading provider of teaching and training courses regarding such techniques as Toxins injections, Fillers, Mezotherapy, PRP, Thread lift. Igor Rudenko has managed a number of clinical trials within oncology, cardiology, dermatology and respiratory areas. He took part into protocol development and finalization, safety managing, regulatory affairs. Igor Rudenko is an active member of aesthetic dermatological professional community through memberships and leadership roles.

igor_rudenko@yahoo.com